Sales Performance - Immuron Limited reported strong sales growth for Travelan®, with total sales of AUD $1.5 million in the September 2024 Quarter, representing a 13% increase compared to the prior quarter [1] - Sales in Australia increased by 3% to AUD $1.007 million in the September 2024 Quarter, up from AUD $0.983 million in the June 2024 Quarter [2] - North American sales saw a significant increase of 48%, reaching AUD $0.456 million in the September 2024 Quarter compared to AUD $0.309 million in the June 2024 Quarter [3] Market Expansion - The company has secured core ranging in nine additional pharmacy banner groups in Australia, enhancing its market presence [2] - Immuron achieved its strongest monthly sales on amazon.com in the US, indicating robust demand in the North American market [2] - Distribution has expanded to ten pharmacy and grocery retailers in Canada, further solidifying the company's footprint in North America [2] Product Overview - Travelan® is an orally administered passive immunotherapy designed to reduce the likelihood of travelers' diarrhea, which is commonly caused by pathogenic bacteria [3] - The product is a purified tablet preparation of hyper-immune bovine antibodies, which bind to diarrhea-causing bacteria and prevent their colonization [3] - Travelan® is registered as a medicine in Australia and as a licensed natural health product in Canada, while in the U.S., it is marketed as a dietary supplement [3]

Core Viewpoint - Immuron Limited has announced the completion of an interim analysis for a clinical evaluation of a new oral therapeutic targeting Campylobacter and Enterotoxigenic Escherichia coli (ETEC) in collaboration with the US Naval Medical Research Command (NMRC) [1][2] Company Overview - Immuron Limited is an Australian biopharmaceutical company focused on developing and commercializing orally delivered targeted polyclonal antibodies for the treatment of infectious diseases [14] - The company has developed two commercially available oral immunotherapeutic products for gut-mediated diseases [1] Clinical Trial Details - The NMRC funded the clinical trial, which involved a hyperimmune bovine colostrum product developed by Immuron using a conjugated vaccine targeting Campylobacter and ETEC [3][4] - The trial enrolled 27 volunteers in a randomized, placebo-controlled study, demonstrating a 10.4% protective efficacy against moderate to severe campylobacteriosis compared to the placebo group [5] Future Plans - Immuron plans to hold an end of Phase 2 meeting with the U.S. Food and Drug Administration (FDA) to initiate Phase 3 clinical trials of Travelan® in the second half of 2025 [2] - The company anticipates topline results from a clinical study of Travelan® involving 866 participants, with 85% recruitment completed and results expected in April 2025 [2] Product Information - Travelan® is an orally administered passive immunotherapy that reduces the likelihood of contracting traveler's diarrhea, caused by pathogenic bacteria [12] - The product is available in Australia as a listed medicine and in Canada as a licensed natural health product, while in the U.S., it is sold as a dietary supplement for digestive tract protection [12] Industry Context - Infectious diarrhea is a common illness among travelers and military personnel, with a high priority for preventative treatments due to increasing antibiotic resistance among enteric pathogens [10] - The NMRC is developing new vaccines targeting Campylobacter and ETEC, as well as other pathogens, in collaboration with Immuron [8]

Dublin, Sept. 19, 2024 (GLOBE NEWSWIRE) -- The "Traveler's Diarrhea - Pipeline Insight, 2024" clinical trials has been added to ResearchAndMarkets.com's offering. This "Traveler's Diarrhea - Pipeline Insight, 2024" report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in Traveler's Diarrhea pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administr ...

Key Points Immuron completes pre-IND meeting with FDA on the development of IMM-529 as product to specifically prevent or treat Clostridioides difficile infection (CDI) Previous clinical trial data on IMM-529 provides support for continued development of IMM-529 Investigational new drug (IND) application for IMM-529 planned for 1H 2025 MELBOURNE, Australia, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company, is p ...

Highlights: $3.5 (USD $2.3) million funding for NMRC and WRAIR approved by the U.S. Department of Defense to advance the development of Travelan. MELBOURNE, Australia, Aug. 16, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce the funding of a new research agreement for the Naval Medical Research Command (NMRC), and Walter Reed Army Institute of Research (WRAIR) Silver Spring, MD, USA. The focus of ...

MELBOURNE, Australia, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN) is pleased to invite shareholders to attend an investor webinar on MarketOpen Direct Connect to be held on: Thursday 8th August 2024, 11:00am Australian Eastern Standard Time (9:00am AWST). Chief Executive Officer, Steven Lydeamore will provide an update on additional data analysis of IMM-124E (Travelan®) Phase 2 trial and next steps. Following the presentation, attendees will have the opportunity to ask questio ...

Global • FY 2024 AUD$4.9 million up 174% on prior comparative period (pcp) • June 2024 Quarter AUD$1.3 million up 253% on pcp and 6% on prior quarter USA • FY 2024 Record sales of AUD$1.1 million up 74% on pcp • June 2024 Quarter AUD$0.3 million up 546% on pcp; down 1% on prior quarter MELBOURNE, Australia, July 15, 2024 (GLOBE NEWSWIRE) -- Immuron Limited ((ASX: IMC, NASDAQ:IMRN), an Australian based and globally integrated biopharmaceutical company, is pleased to announce record sales (unaudited) of Trave ...

MELBOURNE, Australia, July 02, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company, is pleased to announce that it has filed a pre-IND (investigational new drug) application with the United States Food and Drug Administration (FDA) for IMM-529. The increased incidence of antibiotic resistant 'superbugs' has amplified the use of broad-spectrum antibiotics worldwide. An unintended consequence of antimicrobial treatment is dis ...

Core Viewpoint - Immuron Limited has filed a pre-IND application with the FDA for its investigational drug IMM-529, aimed at addressing Clostridioides difficile infection (CDI) and its associated health threats [1][8]. Industry Context - The rise of antibiotic-resistant 'superbugs' has led to increased use of broad-spectrum antibiotics, which disrupts gastrointestinal microbiota and increases susceptibility to opportunistic pathogens like C. diff [2]. - CDI affects over 400,000 individuals annually in the US, resulting in over 30,000 deaths, highlighting the urgent need for new therapeutics to reduce antibiotic reliance [2]. Company Development - Immuron is collaborating with Monash University to develop IMM-529, which utilizes bovine colostrum-derived antibodies targeting key virulence components of C. diff [3]. - IMM-529 is the only investigational drug showing therapeutic potential across all three phases of CDI [4]. Clinical and Market Potential - IMM-529 is being developed as an adjunctive therapy to standard antibiotics for preventing and treating recurrent CDI, with promising pre-clinical results [8][9]. - The drug targets spores, vegetative cells, and Toxin B of C. diff, with pre-clinical models showing an 80% prevention rate for primary disease and a 67% protection rate against recurrence [9]. - If positioned for second recurrence, approximately 31,000 patients could be eligible, with potential yearly revenue projected at $93 million based on conservative estimates [11]. Technology Platform - Immuron's proprietary technology involves producing polyclonal immunoglobulins from engineered hyper-immune bovine colostrum, which are orally active and can withstand the gastrointestinal environment [13].

MELBOURNE, Australia, June 05, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce that our Chief Executive Officer, Steven Lydeamore has been invited to present at the Emerging Growth Conference on June 13th, 2024. Immuron Limited invites individual and institutional investors as well as advisors and analysts, to attend its real-time, interactive presentation at the Emerging Growth Conference. Mr. St ...